|
1
|
Xu Z, Jiang H, Zhu Y, Wang H, Jiang J,
Chen L, Xu W, Hu T and Cho CH: Cryptotanshinone induces
ROS-dependent autophagy in multidrug-resistant colon cancer cells.
Chem Biol Interact. 273:48–55. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Udawat H, Nunia V, Mathur P, Udawat HP,
Gaur KL, Saxena AK and Mohan MK: Histopathological and
immunohistochemical findings in congenital pouch colon: A
prospective study. Pathobiology. 84:202–209. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Senol S, Ceyran AB, Kösemetin D, Gobanoglu
B, Aydin D, Duran EA and Leblebici M: Immunohistochemical profile
of tumor pathways and prognostic significance in colon
adenocarcinomas. J Environ Pathol Toxicol Oncol. 36:29–41. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hakoda K, Yoshimitsu M, Emi M, Omori I,
Kohashi T, Kaneko M, Ohdan H and Hirabayashi N: Complete
pathological response of multiple huge liver metastases of colon
cancer: A case report. Oxf Med Case Reports. 2017:omx0162017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sloothaak DAM, van der Linden RLA, van de
Velde CJH, Bemelman WA, Lips DJ, van der Linden JC, Doornewaard H,
Tanis PJ, Bosscha K, van der Zaag ES, et al: Prognostic
implications of occult nodal tumour cells in stage I and II colon
cancer: The correlation between micrometastasis and disease
recurrence. Eur J Surg Oncol. 43:1456–1462. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nakamura Y, Hattori N, Iida N, Yamashita
S, Mori A, Kimura K, Yoshino T and Ushijima T: Targeting of
super-enhancers and mutant BRAF can suppress growth of BRAF-mutant
colon cancer cells via repression of MAPK signaling pathway. Cancer
Lett. 402:100–109. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guo J, Wu Y, Yang L, Du J, Gong K, Chen W,
Dai J, Li X and Xi S: Repression of YAP by NCTD disrupts NSCLC
progression. Oncotarget. 8:2307–2319. 2017.PubMed/NCBI
|
|
8
|
Azzolin L, Panciera T, Soligo S, Enzo E,
Bicciato S, Dupont S, Bresolin S, Frasson C, Basso G, Guzzardo V,
et al: YAP/TAZ incorporation in the β-catenin destruction complex
orchestrates the Wnt response. Cell. 158:157–170. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Martin K, Pritchett J, Llewellyn J, Mullan
AF, Athwal VS, Dobie R, Harvey E, Zeef L, Farrow S, Streuli C, et
al: PAK proteins and YAP-1 signalling downstream of integrin beta-1
in myofibroblasts promote liver fibrosis. Nat Commun. 7:125022016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Moleirinho S, Hoxha S, Mandati V, Curtale
G, Troutman S, Ehmer U and Kissil JL: Regulation of localization
and function of the transcriptional co-activator YAP by angiomotin.
eLife. 6:e239662017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tranchant R, Quetel L, Tallet A, Meiller
C, Renier A, de Koning L, de Reynies A, Le Pimpec-Barthes F,
Zucman-Rossi J, Jaurand MC, et al: Co-occurring mutations of tumor
suppressor genes, LATS2 and NF2, in malignant pleural mesothelioma.
Clin Cancer Res. 23:3191–3202. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Feng G, Zhu Z, Li WJ, Lin Q, Chai Y, Dong
MQ and Ou G: Hippo kinases maintain polarity during directional
cell migration in Caenorhabditis elegans. EMBO J. 36:334–345. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang L, Luo JY, Li B, Tian XY, Chen LJ,
Huang Y, Liu J, Deng D, Lau CW, Wan S, et al: Integrin-YAP/TAZ-JNK
cascade mediates atheroprotective effect of unidirectional shear
flow. Nature. 12:72016.
|
|
14
|
Moroishi T, Hayashi T, Pan WW, Fujita Y,
Holt MV, Qin J, Carson DA and Guan KL: The Hippo pathway kinases
LATS1/2 suppress cancer immunity. Cell. 167:1525–1539.e17. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sharif GM and Wellstein A: Cell density
regulates cancer metastasis via the Hippo pathway. Future Oncol.
11:3253–3260. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim T, Hwang D, Lee D, Kim JH, Kim SY and
Lim DS: MRTF potentiates TEAD-YAP transcriptional activity causing
metastasis. EMBO J. 36:520–535. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yamamoto M, Ohsawa S, Kunimasa K and Igaki
T: The ligand Sas and its receptor PTP10D drive tumour-suppressive
cell competition. Nature. 542:246–250. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiao S, Li C, Hao Q, Miao H, Zhang L, Li L
and Zhou Z: VGLL4 targets a TCF4-TEAD4 complex to coregulate Wnt
and Hippo signalling in colorectal cancer. Nat Commun. 8:140582017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Oun R and Rowan E: Cisplatin induced
arrhythmia; electrolyte imbalance or disturbance of the SA node?
Eur J Pharmacol. 811:125–128. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Alterio D, Rocca Cossu M, Russell-Edu W,
Dicuonzo S, Fanetti G, Marvaso G, Preda L, Zorzi S, Verri E, Nole'
F, et al: Med Oncol. 34:862017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang F, Yu X, Liu X, Zhou T, Nie T, Cheng
M, Liu H, Dai M and Zhang B: ABT-737 potentiates cisplatin-induced
apoptosis in human osteosarcoma cells via the mitochondrial
apoptotic pathway. Oncol Rep. 38:2301–2308. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang J, Kho DH, Zhou JY, Davis RJ and Wu
GS: MKP-1 suppresses PARP-1 degradation to mediate cisplatin
resistance. Oncogene. 36:5939–5947. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen LG, Xia YJ and Cui Y: Upregulation of
miR-101 enhances the cytotoxic effect of anticancer drugs through
inhibition of colon cancer cell proliferation. Oncol Rep.
38:100–108. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu M, Tang X, Guo J, Sun W and Tang F:
Reversal effect of adenovirus-mediated human interleukin 24
transfection on the cisplatin resistance of A549/DDP lung cancer
cells. Oncol Rep. 38:2843–2851. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jacobs J, Deschoolmeester V, Rolfo C,
Zwaenepoel K, Van den Bossche J, Deben C, Silence K, de Haard H,
Hermans C, Rottey S, et al: Preclinical data on the combination of
cisplatin and anti-CD70 therapy in non-small cell lung cancer as an
excellent match in the era of combination therapy. Oncotarget.
8:74058–74067. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mukherjee S, Dash S, Lohitesh K and
Chowdhury R: The dynamic role of autophagy and MAPK signaling in
determining cell fate under cisplatin stress in osteosarcoma cells.
PLoS One. 12:e01792032017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li L, Duan W, Zhang L, Li X, Fu X, Wang X,
Wu J, Sun Z, Zhang X, Chang Y, et al: The efficacy and safety of
gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in
patients with newly diagnosed peripheral T-cell lymphoma with
analysis of biomarkers. Br J Haematol. 178:772–780. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Choi BY, Joo JC, Lee YK, Jang IS, Park SJ
and Park YJ: Anti-cancer effect of Scutellaria baicalensis in
combination with cisplatin in human ovarian cancer cell. BMC
Complement Altern Med. 17:2772017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rudolph C, Melau C, Nielsen JE, Jensen
Vile K, Liu D, Pena-Diaz J, Rajpert-De Meyts E, Rasmussen LJ and
Jørgensen A: Involvement of the DNA mismatch repair system in
cisplatin sensitivity of testicular germ cell tumours. Cell Oncol
(Dordr). 40:341–355. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ge L, Li DS, Chen F, Feng JD, Li B and
Wang TJ: TAZ overexpression is associated with
epithelial-mesenchymal transition in cisplatin-resistant gastric
cancer cells. Int J Oncol. 51:307–315. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Akdemir Ekinci FN, Albayrak M, Calik M,
Bayir Y and Gulcin I: The protective effects of p-coumaric acid on
acute liver and kidney damages induced by cisplatin. Biomedicines.
5:E182017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Győrffy B, Surowiak P, Budczies J and
Lánczky A: Online survival analysis software to assess the
prognostic value of biomarkers using transcriptomic data in
non-small-cell lung cancer. PLoS One. 8:e822412013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ma B, Cheng H, Gao R, Mu C, Chen L, Wu S,
Chen Q and Zhu Y: Zyxin-Siah2-Lats2 axis mediates cooperation
between Hippo and TGF-β signalling pathways. Nat Commun.
7:111232016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gaspar P, Holder MV, Aerne BL, Janody F
and Tapon N: Zyxin antagonizes the FERM protein expanded to couple
F-actin and Yorkie-dependent organ growth. Curr Biol. 25:679–689.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang J, Chen Y, Xiang F, Li M, Li H, Chi J
and Ren K: Suppression of TGF-β1 enhances chemosensitivity of
cisplatin-resistant lung cancer cells through the inhibition of
drug-resistant proteins. Artif Cells Nanomed Biotechnol. 8:1–8.
2017. View Article : Google Scholar
|
